vs

Side-by-side financial comparison of Cellectis S.A. (CLLS) and Marti Technologies, Inc. (MRT). Click either name above to swap in a different company.

Marti Technologies, Inc. is the larger business by last-quarter revenue ($14.6M vs $9.5M, roughly 1.5× Cellectis S.A.). On growth, Cellectis S.A. posted the faster year-over-year revenue change (375.0% vs 63.1%).

Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.

The Marti Group is a Swiss construction company, consisting of over 80 subsidiaries, officially owned by Marti Holding AG. Besides Switzerland, they are active in neighboring countries such as Germany and Austria, and also outside of Europe such as China and Chile. The company is known for high-profile public and private sector projects and using innovative technologies. Their areas of expertise include building construction, construction and renovation of tunnels, road construction, hydrauli...

CLLS vs MRT — Head-to-Head

Bigger by revenue
MRT
MRT
1.5× larger
MRT
$14.6M
$9.5M
CLLS
Growing faster (revenue YoY)
CLLS
CLLS
+311.9% gap
CLLS
375.0%
63.1%
MRT

Income Statement — Q2 FY2024 vs Q2 FY2025

Metric
CLLS
CLLS
MRT
MRT
Revenue
$9.5M
$14.6M
Net Profit
$-25.3M
Gross Margin
49.4%
Operating Margin
-181.1%
-86.1%
Net Margin
-265.9%
Revenue YoY
375.0%
63.1%
Net Profit YoY
-51.9%
EPS (diluted)
$-0.28
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLLS
CLLS
MRT
MRT
Q2 25
$14.6M
Q2 24
$9.5M
$8.9M
Q3 23
$1.6M
Q2 23
$2.0M
Q2 22
$2.7M
Net Profit
CLLS
CLLS
MRT
MRT
Q2 25
Q2 24
$-25.3M
Q3 23
$-17.5M
Q2 23
$-16.6M
Q2 22
$-19.5M
Gross Margin
CLLS
CLLS
MRT
MRT
Q2 25
49.4%
Q2 24
Q3 23
Q2 23
97.3%
Q2 22
87.9%
Operating Margin
CLLS
CLLS
MRT
MRT
Q2 25
-86.1%
Q2 24
-181.1%
-204.1%
Q3 23
-1258.1%
Q2 23
-1180.5%
Q2 22
-1003.0%
Net Margin
CLLS
CLLS
MRT
MRT
Q2 25
Q2 24
-265.9%
Q3 23
-1064.1%
Q2 23
-831.6%
Q2 22
-714.4%
EPS (diluted)
CLLS
CLLS
MRT
MRT
Q2 25
$-0.26
Q2 24
$-0.28
$-0.38
Q3 23
$-0.31
Q2 23
$-0.20
Q2 22
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLLS
CLLS
MRT
MRT
Cash + ST InvestmentsLiquidity on hand
$149.0M
$4.2M
Total DebtLower is stronger
$83.0M
Stockholders' EquityBook value
$148.6M
$-73.2M
Total Assets
$407.1M
$17.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLLS
CLLS
MRT
MRT
Q2 25
$4.2M
Q2 24
$149.0M
$9.0M
Q3 23
Q2 23
$84.4M
Q2 22
$129.4M
Total Debt
CLLS
CLLS
MRT
MRT
Q2 25
$83.0M
Q2 24
$60.2M
Q3 23
Q2 23
Q2 22
Stockholders' Equity
CLLS
CLLS
MRT
MRT
Q2 25
$-73.2M
Q2 24
$148.6M
$-51.2M
Q3 23
$76.1M
Q2 23
$96.6M
Q2 22
$180.5M
Total Assets
CLLS
CLLS
MRT
MRT
Q2 25
$17.2M
Q2 24
$407.1M
$25.0M
Q3 23
$209.7M
Q2 23
$227.7M
Q2 22
$320.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLLS
CLLS
MRT
MRT
Operating Cash FlowLast quarter
$28.9M
Free Cash FlowOCF − Capex
$27.6M
FCF MarginFCF / Revenue
290.5%
Capex IntensityCapex / Revenue
13.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLLS
CLLS
MRT
MRT
Q2 25
Q2 24
$28.9M
Q3 23
Q2 23
$-47.4M
Q2 22
$-60.2M
Free Cash Flow
CLLS
CLLS
MRT
MRT
Q2 25
Q2 24
$27.6M
Q3 23
Q2 23
$-47.9M
Q2 22
$-61.7M
FCF Margin
CLLS
CLLS
MRT
MRT
Q2 25
Q2 24
290.5%
Q3 23
Q2 23
-2391.4%
Q2 22
-2266.7%
Capex Intensity
CLLS
CLLS
MRT
MRT
Q2 25
Q2 24
13.2%
Q3 23
Q2 23
24.1%
Q2 22
56.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons